×

Seres Therapeutics, Inc. (Nasdaq: MCRB) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Aug. 19, 2015 (GLOBE NEWSWIRE) --

What:

Seres Therapeutics, Inc. (Nasdaq:MCRB), a leading microbiome therapeutics platform company, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Roger Pomerantz, President and Chief Executive Officer, will ring the Closing Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Thursday, August 20, 2015 – 3:45 p.m. to 4:00 p.m. ET

Seres Therapeutics, Inc. Media Contact:

Amanda Guisbond

617.761.6797

amanda.guisbond@fkhealth.com

Nasdaq MarketSite:

Angela Tu

(646) 225-0316

Angela.Tu@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463


Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page:

http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page:

http://nasdaq.tumblr.com/

Webcast:
A webcast of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Seres Therapeutics, Inc. (Nasdaq:MCRB):

Seres Therapeutics, Inc., is a microbiome therapeutics platform company developing a novel class of biological drugs, which are designed to treat disease by restoring the function of a dysbiotic microbiome.

SER-109 is Seres’ lead Ecobiotic® microbiome therapeutic in Phase 2 clinical testing for the treatment of recurrent Clostridium Difficile infection (CDI). SER-109 was developed utilizing the Seres Microbiome Therapeutics™ platform that provides insight into the ecologies of disease and then identifies microbial compositions that can catalyze a shift to health. CDI is a growing problem associated with antibiotic use. Approximately 85,000 to 110,000 CDI patients in the U.S. are expected to have more than one recurrence.

For more information, visit www.serestherapeutics.com.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $9.6 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-

Source:The NASDAQ OMX Group, Inc.